DWJ155 for Breast Cancer

This trial tests a new treatment called [177Lu]Lu-DWJ155, a radiopharmaceutical therapy, for its safety and initial effectiveness in fighting tumors. It targets individuals with advanced breast, lung, gastric, and bladder cancers who have not responded to standard treatments. Participants will receive varying doses to determine the most effective amount. This trial may suit those whose cancer has progressed despite previous therapies and who seek alternative options. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial information does not specify if you need to stop taking your current medications. However, certain treatments like recent radiopharmaceuticals or radiation therapy have specific time restrictions before joining the trial.

A previous study found that the treatment [177Lu]Lu-DWJ155 was in the early stages of testing, indicating limited information on its safety. The study focuses on assessing its safety and tolerability, including any side effects. For [68Ga]Ga-DWJ155, early research suggests it is primarily tested for its imaging capabilities. The study also evaluates its safety and how the body processes it.

Researchers are excited about [177Lu]Lu-DWJ155 for breast cancer because it represents a novel approach by using radiolabeled compounds. Unlike traditional treatments such as chemotherapy and hormone therapy, which rely on systemic effects, [177Lu]Lu-DWJ155 specifically targets cancer cells with a radioactive isotope, potentially reducing side effects and increasing precision. Additionally, the treatment includes a dose escalation phase to determine optimal dosing for maximum efficacy, which could lead to more personalized treatment strategies. This targeted approach promises to advance the way we treat breast cancer by directly attacking cancer cells while sparing healthy tissue.

Research has shown that treatments using radioactive substances, such as [177Lu]Lu-DWJ155, hold promise for treating advanced cancers, including breast cancer. In this trial, participants in the Dose Escalation arm will receive [68Ga]Ga-DWJ155 and, if eligible, [177Lu]Lu-DWJ155 at various dose levels. The Dose Expansion arm will administer [68Ga]Ga-DWJ155 and, if eligible, [177Lu]Lu-DWJ155 at the recommended dose established during the dose escalation phase. Studies found that a similar treatment achieved a 74% success rate in patients with hormone receptor-positive breast cancer, suggesting it might effectively target certain cancer cells. Although more research is needed to confirm these results specifically for [177Lu]Lu-DWJ155, early data offers hope that this treatment could help shrink tumors or slow their growth in patients with advanced breast cancer.²⁴⁵⁶⁷